Table 1.
Baseline Characteristics of the 56 Patients with Advanced NSCLC
| Characteristics | Total Patients (N=56) | Percentage |
|---|---|---|
| Age (years) | ||
| Median (range) | 65 (21–81) | |
| ≥65 | 30 | 53.6% |
| <65 | 26 | 46.4% |
| ECOG performance status score | ||
| 0–1 | 25 | 44.6% |
| 2 | 31 | 55.4% |
| Gender | ||
| Male | 37 | 66.1% |
| Female | 19 | 33.9% |
| Pathological staging | ||
| IIIb | 7 | 12.5% |
| IV | 49 | 87.5% |
| Smoking status | ||
| Nonsmoker | 11 | 19.6% |
| Former smoker/smoker | 45 | 80.4% |
| Histological category | ||
| Adenocarcinoma | 37 | 66.1% |
| Squamous cell carcinoma | 19 | 33.9% |
| Lines of previous treatment | ||
| First-line | 11 | 19.6% |
| Second-line or more | 45 | 80.4% |
| Presence of brain metastases | ||
| Yes | 9 | 16.1% |
| No | 47 | 83.9% |
| History of surgical resection | ||
| Yes | 18 | 32.1% |
| No | 38 | 67.9% |
| EGFR mutation status | ||
| Positive | 19 | 33.9% |
| Negative | 37 | 66.1% |
| TP53 mutation status | ||
| Positive | 28 | 50.0% |
| Negative | 23 | 41.1% |
| NA | 5 | 8.9% |
| Number of metastatic lesions | ||
| ≤3 | 31 | 55.4% |
| >3 | 25 | 44.6% |
| Initial dosage of anlotinib (mg) | ||
| 12 | 35 | 62.5% |
| 10 | 21 | 37.5% |
| Immunotherapy | ||
| Camrelizumab | 23 | 41.1% |
| Tislelizumab | 16 | 28.6% |
| Pembrolizumab | 11 | 19.6% |
| Nivolumab | 6 | 10.7% |